Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report

BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive malignancy with high morbidity and mortality. Conversion therapy can improve surgical resection rate and prolong survival time for patients with advanced HCC. We show that combination therapy with lenvatinib and camrelizumab is a novel appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhihong, Chen, Zhenrong, Fan, Wu, Zou, Yiping, Zhang, Yuanpeng, Shi, Ning, Jin, Haosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887816/
https://www.ncbi.nlm.nih.gov/pubmed/36721173
http://dx.doi.org/10.1186/s12957-023-02910-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887816/
https://www.ncbi.nlm.nih.gov/pubmed/36721173
http://dx.doi.org/10.1186/s12957-023-02910-4

Ejemplares similares